IP Verse

Pharmaceutical Formulations Comprising 4-{(1 R)-2-[(6-{2-[(2,6-Dichlorobenzyl)Oxy]Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2-(Hydroxymethyl)Phenol - EP3578169B1

PatentPatent Analysis

EP3578169

GLAXO GROUP
Application Number
EP19175120A
Filing Date
Feb 26, 2009
Status
Granted And Under Opposition
May 24, 2024
Grant Date
Jun 26, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3335707B1
EP1907037B2
EP2005372B1

Bibliography

The patent EP3578169B1 was granted to Glaxo Group on Jun 26, 2024 following the initial filing on Feb 26, 2009 under the application number EP19175120A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 27, 2024 -

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents